Tesamorelin 10mg Research Peptide

For Research Purposes Only. Not approved for human consumption.

Tesamorelin Research Peptide 10mg

Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) specifically engineered with a trans-3-hexenoic acid group to increase resistance to degradation and improve pharmacokinetics. It has been FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy, making it one of the few research peptides with established clinical data in a specific metabolic condition. Tesamorelin serves as an important reference compound for researchers studying GHRH analogs in metabolic and body composition research.

Research Applications

• GHRH analog pharmacokinetic research
• Visceral adipose tissue and metabolic studies
• HIV-associated lipodystrophy research models
• GH axis and IGF-1 elevation studies
• Body composition and lipodystrophy research

Quality Specifications

• Purity: ≥98% (HPLC verified)
• Compound: Tesamorelin
• Molecular Weight: 5135.9 Da
• Form: Lyophilized powder
• Storage: -20°C, protect from light
• COA: Batch-specific, ISO-accredited laboratory

Frequently Asked Questions

Q: How does Tesamorelin differ from other GHRH analogs?
A: Tesamorelin has a trans-3-hexenoic acid modification for enhanced stability. It is FDA-approved for HIV-associated lipodystrophy — one of the few peptides with clinical approval for a specific indication.

Q: What is lipodystrophy?
A: Abnormal fat distribution — either loss (lipoatrophy) or accumulation (lipohypertrophy). Tesamorelin is approved specifically for HIV-associated abdominal lipohypertrophy.

Q: Why is Tesamorelin significant for research?
A: Its FDA-approved status provides extensive clinical safety and efficacy data, making it a valuable reference compound when studying newer GHRH analogs.

Related Research: CJC-1295 No DAC | Sermorelin | Ipamorelin

For laboratory research use only. Not for human consumption. Not evaluated by the FDA.